Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: New opportunities for therapy

Endocrine-Related Cancer

Volumn 11, Issue 4, 2004, Pages 623-641

  Nicholson, R I ^a   Staka, C ^a   Boyns, F ^a   Hutcheson, I R ^a   Gee, J M W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 AZA 2' DEOXYCYTIDINE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; FIBROBLAST GROWTH FACTOR 4; FULVESTRANT; GEFITINIB; GROWTH FACTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN B; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TRICHOSTATIN A;

AUTOCRINE EFFECT; BREAST CANCER; CANCER SURVIVAL; CELL CYCLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; ESTROGEN RESPONSIVE ELEMENT; GENE OVEREXPRESSION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; GROWTH SUBSTANCES; HUMANS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 11244250660     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00778     Document Type: Review

References (153)

1. Abdul-Wahab K, Corcoran D, Perachiotti A & Darbre PD 1999 Overexpression of insulin-like growth factor II (IGFII) in ZR-75-71 human breast cancer cells: higher threshold levels of receptor (IGFIR) are required for a proliferative response than for effects on specific gene expression. Cell Proliferation 32 271-287.
2. van Agthoven T, van Agthoven TL, Portengen H, Foekens JA & Dorssers LC 1992 Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-71 human breast cancer cells. Cancer Research 52 5082-5088.
3. van Agthoven T, van Agthoven TL, Dekker A, Foekens JA & Dorssers LC 1994 Induction of estrogen independence of ZR-75-71 human breast cancer cells by epigenetic alterations. Molecular Endocrinology 8 1474-1483.
4. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK & Milas L 1999 Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clinical Cancer Research 5 2884-2890.
5. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD & Pietenpol JA 1993 Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth and Differentiation 4 193-201.
6. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C & Lupu R 2003 Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Molecular Cancer Research 1 165-175.
7. Bates NP & Hurst HC 1997 An intron 1 enhancer element mediates estrogen-induced suppression of ERBB2 expression. Oncogene 15 473-481.
8. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A & Sahmoud T; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group 2003 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 1802-1810.
9. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE & Whitesell L 2003 Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clinical Cancer Research 9 4961-4971.
10. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM & Osborne CK 1993 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 24 85-95.
11. van den Berg HW, Claffie D, Boylan M, McKillen J, Lynch M & McKibben B 1996 Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-71 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor 1 receptor expression. British Journal of Cancer 73 477-481.
12. Berstein LM, Zheng H, Yue W, Wang JP, Lykkesfeldt AE, Naftolin F, Harada H, Shanabrough M & Santen RJ 2003 New approaches to the understanding of tamoxifen action and resistance. Endocrine-Related Cancer 10 267-277.
13. Berstein LM, Wang JP, Zheng H, Yue W, Conaway M & Santen RJ 2004 Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clinical Cancer Research 10 1530-1534.
14. Biswas DK, Cruz AP, Gansberger E & Pardee AB 2000 Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. PNAS 97 8542-8547.
15. Britton D, Hutcheson IR, Barrow D, Gee JMW & Nicholson RI 2002 Increased estrogen receptor phosphorylation at serine 118 in tamoxifen resistant MCF-7 breast cancer cells. Biochemical Society Transactions 31 P114.
16. Britton D, Hutcheson IR, Barrow D, McClelland RA & Nicholson RI 2003 Estrogen receptor phosphorylation in hormone sensitive and anti-hormone resistant breast cancer cells. Breast Cancer Research and Treatment 82 S61.
17. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
18. Buzdar AU, Jonat W, Howell A & Plourde PV 1997 ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology 61 145-149.
19. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/ AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817-9824.
20. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV & Auricchio F 2001 PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO Journal 20 6050-6059.
21. Chan CM, Martin LA, Johnston SR, Ali S & Dowsett M 2002 Molecular changes associated with the acquisition of estrogen hypersensitivity in MCF-7 breast cancer cells on long-term estrogen deprivation. Journal of Steroid Biochemistry and Molecular Biology 81 333-341.
22. Chen Z, Ke LD, Yuan XH & Adler-Storthz K 2000 Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Research 20 899-902.
23. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC & Tonetti DA 2001 Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha. Clinical Cancer Research 7 3156-3165.
24. Chrysogelos SA, Yarden RI, Lauber AH & Murphy JM 1994 Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Research and Treatment 31 227-236.
25. Chung YL, Sheu ML, Yang SC, Lin CH & Yen SH 2002 Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. International Journal of Cancer 97 306-312.
26. Ciardiello F & Tortora G 2001 A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clinical Cancer Research 7 2958-2970.
27. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y & Hilakivi-Clarke LA 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22 7316-7339.
28. Coutts AS & Murphy LC 1998 Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Research 58 4071-4074.
29. Daly RJ, King RJ & Darbre PD 1990 Interaction of growth factors during progression towards steroid independence in T-47-D human breast cancer cells. Journal of Cell Biochemistry 43 199-211.
30. Daly RJ, Harris WH, Wang DY & Darbre PD 1991 Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth and Differentiation 2 457-464.
31. Darbre PD & Daly RJ 1990 Transition of human breast cancer cells from an estrogen responsive to unresponsive state. Journal of Steroid Biochemistry and Molecular Biology 37 753-763.
32. Demirpence E, Pons M, Balaguer P & Gagne D 1992 Study of an antiestrogenic effect of retinoic acid in MCF-7 cells. Biochemical and Biophysical Research Communications 183 100-106.
33. Dickstein BM, Wosikowski K & Bates SE 1995 Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Molecular and Cellular Endocrinology 110 205-211.
34. Donovan JC, Milic A & Slingerland JM 2001 Constitutive MEK/ MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. Journal of Biological Chemistry 276 40888-40895.
35. Doucas V & Yaniv M 1991 Functional interaction between estrogen receptor and proto-oncogene products c-Jun and c-Fos. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiale 185 464-474.
36. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N & Smith I 2001 HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Research 61 8452-8458.
37. Dowsett MC, Gutierrez S, Mohsin R, Schiff S, Detre S, Johnston & Osborne CK 2003 Molecular changes in tamoxifen-relapsed breast cancer: relationship between ER, HER2 and P38-MAP-kinase. Proceedings for the American Society of Clinical Oncology 22 3 (Abstract 7).
38. Dunn SE, Hardman RA, Kari FW & Barrett JC 1997 Insulin-like growth factor I (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Research 57 2687-2693.
39. El-Ashry D, Miller DL, Kharbanda S, Lippman ME & Kern FG 1997 Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15 423-435.
40. Elliott RL, Elliott MC, Wang F & Head JF 1993 Breast carcinoma and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study. Annals of the New York Academy of Sciences 698 159-166.
41. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E & Borgs M. 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology 19 3808-3816.
42. de Fazio A, Chiew YE, McEvoy M, Watts CK & Sutherland RL 1997 Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth and Differentiation 8 903-911.
43. Fernandez P, Wilson C, Hoivik D & Safe SH 1998 Altered phenotypic characteristics of T47d human breast cancer cells after prolonged growth in estrogen-deficient medium. Cell Biology International 22 623-633.
44. Figtree GA, Webb CM & Collins P 2000 Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. Journal of Pharmacology and Experimental Therapeutics 295 519-523.
45. Font de Mora J & Brown M 2000 AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Molecular and Cellular Biology 20 5041-5047.
46. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P & Allred DC 2000 A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Research 60 4026-4029.
47. Gee JM & Nicholson RI 2003 Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Research 5 126-129. Epub 2003 Feb 20.
48. Gee JM, Willsher PC, Kenny FS, Robertson JF, Pinder SE, Ellis IO & Nicholson RI 1999 Endocrine response and resistance in breast cancer: a role for the transcription factor Fos. International Journal of Cancer 84 54-61.
49. Gee JM, Robertson JF, Ellis 10 & Nicholson RI 2001 Phosphorylation of ERK 1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. International Journal of Cancer 95 247-254.
50. Gee JMW, Madden TA, Robertson JFR & Nicholson RI 2002 Clinical response and resistance to SERMS. In Endocrine Therapy in Breast Cancer, pp 155-190. Eds JFR Robertson, RI Nicholson & DF Hayes. London: Martin Dunitz Ltd.
51. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE & Nicholson RI 2003 The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144 5105-5117. Epub 2003 Aug 07.
52. Gooch JL, Van Den Berg CL & Yee D 1999 Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy induced cell death - proliferative and anti-apoptotic effects. Breast Cancer Research and Treatment 56 1-10.
53. Gottardis MM & Jordan VC 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 48 5183-5187.
54. Gross JM & Yee D 2003 The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. Cancer and Metastasis Review 22 327-336.
55. Guvakova MA & Surmacz E 1997 Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Experimental Cell Research 231 149-162.
56. Herman ME & Katzenellenbogen BS 1994 Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Research 54 5867-5874.
57. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA & Walton P 1996 Pharmacokinetics, pharmacological and anti-tumor effects of the specific anti-estrogen ICI 182,780 in women with advanced breast cancer. British Journal of Cancer 74 300-308.
58. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I & Osborne CK 2004 Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. Journal of Clinical Oncology 22 1605-1613.
59. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE & Nicholson RI 2003 Estrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 81-93.
60. Hutcheson IR, Knowlden JM, Barrow D & Nicholson RI 2004 IGF-1R/EGFR cross-talk in tamoxifen resistant MCF-7 breast cancer cells. AACR 2004 Proceedings 45 5189.
61. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S & Santen RJ 1998 Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139 4164-4174.
62. Jeng MH, Yue W, Eischeid A, Wang JP & Santen RJ 2000 Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Research and Treatment 62 167-175.
63. Jensen J, Kitlen JW, Briand P, Labrie F & Lykkesfeldt AE 2003 Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. Journal of Steroid Biochemistry and Molecular Biology 84 469-478.
64. Jess TJ, Belham CM, Thomson FJ, Scott PH, Plevin RJ & Gould GW 1996 Phosphatidylinositol 3′-kinase, but not p70 ribosomal S6 kinase, is involved in membrane protein recycling: wortmannin inhibits glucose transport and downregulates cell-surface transferrin receptor numbers independently of any effect on fluid-phase endocytosis in fibroblasts. Cellular Signaling 8 297-304.
65. Johnston SR & Dowsett M 2003 Aromatase inhibitors for breast cancer: lessons from the laboratory. Nature Reviews Cancer 3 821-831.
66. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M & Benz CC 1999 Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clinical Cancer Research 5 251-256.
67. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE & Dowsett M 2003 Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clinical Cancer Research 9 524S-532S.
68. Jones HE, Nicholson RI, Hutcheson IR, Knowlden JM, Harper ME, Jordan N, Hiscox SE, Barrow D & Gee JMW 2004 Endocrine resistance in breast cancer: therapeutic intervention using signal transduction inhibitors. Advances in Breast Cancer 1 3-9.
69. de Jong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH, Lu Q, Jelovac D & Brodie AM 2003 The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. Journal of Steroid Biochemistry and Molecular Biology 87 149-155.
70. Jordan VC, Osipo C, Schafer JM, Fox JE, Cheng D & Liu H 2003 Changing role of the estrogen receptor in the life and death of breast cancer cells. Breast 12 432-441.
71. Jordan NJ, Gee JMW, Barrow D, Wakeling AE & Nicholson RI 2004 Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Research and Treatment 87 167-180.
72. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R & Grohe C 2000 Estrogen receptor alpha rapidly activates the IGF-I receptor pathway. Biological Chemistry 275 18447-18453.
73. Karnik PS, Kulkarni S, Liu XP, Budd GT & Bukowski RM 1994 Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Research 54 349-353.
74. Katzenellenbogen BS, Kendra KL, Norman MJ & Berthois Y 1987 Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Research 47 4355-4360.
75. Knowlden JM, Hutcheson IR, Barrow D & Nicholson RI 2003a IGF-1R and EGFR crosstalk in tamoxifen resistant breast cancer cells. Breast Cancer Research and Treatment 82 S171.
76. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003b Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1032-1044.
77. Kurokawa H & Arteaga CL 2003 ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clinical Cancer Research 9 511S-515S.
78. Li H & Qian ZM 2002 Transferrin/transferrin receptor-mediated drug delivery. Medicinal Research Reviews 22 225-250.
79. Liu Y, El-Ashry D, Chen D, Ding IY & Kern FG 1995 MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen dependence and tamoxifen-sensitivity in vivo. Breast Cancer Research and Treatment 34 97-117.
80. Long B, McKibben BM, Lynch M & van den Berg HW 1992 Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or estrogen independence in the ZR-75-71 human breast cancer cell line. British Journal of Cancer 65 865-869.
81. Long BJ, Jelovac D, Thiantanawat A & Brodie AM 2002 The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clinical Cancer Research 8 2378-2388.
82. Lonning PE 2001 Stepwise estrogen suppression manipulating the estrostat. Journal of Steroid Biochemistry and Molecular Biology 79 127-132.
83. Luftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD & Possinger K 2003 Takeda Adjuvant Breast Cancer Study with Leuprorelin Study Group. Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients. Breast Cancer Research and Treatment 80 245-255.
84. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM & Nicholson RI 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142 2776-2788.
85. McLeskey SW, Kurebayashi J, Honig SF, Zwiebel J, Lippman ME, Dickson RB & Kern FG 1993 Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Research 53 2168-2177.
86. Martin MB, Garcia-Morales P, Stoica A, Solomon HB, Pierce M, Katz D, Zhang S, Danielsen M & Saceda M 1995 Effects of 12-O-tetradecanoylphorbol- 13-acetate on estrogen receptor activity in MCF-7 cells. Journal of Biological Chemistry 270 25244-25251.
87. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C & Dowsett M. 2003 Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. Journal of Biological Chemistry 278 30458-30468. Epub 2003 May 29.
88. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
89. Massarweh S, Shou J, Mohsin SK, Ge M, Wakeling AE, Osborne CK & Schiff R 2002 Inhibition of epidermal growth factor/ HER2 receptor signaling using ZD1839 ('Iressa') restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors. Proceedings for the American Society of Clinical Oncology 21 33 (Abstract).
90. Massarweh SA, Jiang S, Mohsin SK, DiPietro M, Wakeling AE, Osborne CK & Schiff R 2003 Resistance to endocrine therapy in a xenograft model of HER-2 overexpressing breast cancer is accompanied by increased HER-2 but loss of IGF-1 receptor expression. Proceedings for the American Society of Clinical Oncology, 26th Annual Meeting, San Antonio, TX, USA. Abstract 1007.
91. Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW & Kern FG 1994 Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth and Differentiation 5 1263-1274.
92. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA & Dugan M 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Clinical Oncology 19 2596-2606.
93. Mueller H, Kueng W, Schoumacher F, Herzer S, & Eppenberger U 1995 Selective regulation of steroid receptor expression in MCF-7 breast cancer cells by a novel member of the heregulin family. Biochemical and Biophysical Research Communications 217 1271-1278.
94. Munzone EF, Nole G, Renne A, Balduzzi G, Sanna L, Corsetto A & Goldhirsch 2003 Reverting estrogen receptor (ER) negative phenotype in advanced breast cancer patients (pts) over-expressing HER2 after treatment with trastuzumab plus chemotherapy. Proceedings for the American Society of Clinical Oncology 22 848 (Abstract 3409).
95. Murphy CS, Meisner LF, Wu SQ & Jordan VC 1989 Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. European Journal of Cancer and Clinical Oncology 25 1777-1788.
96. Murphy CS, Pink JJ & Jordan VC 1990 Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Research 50 7285-7292.
97. Nicholson RI & Gee JM 2000 Estrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. British Journal of Cancer 82 501-513.
98. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO & Blamey RW 1994 Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Research and Treatment 29 117-125.
99. Nicholson RI, Gee JM & Harper ME 2001a EGFR and cancer prognosis. European Journal of Cancer 37 (Suppl 4) S9-S15.
100. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE & Gee JM 2001b Modulation of epidermal growth factor receptor in endocrine resistant, estrogen receptor-positive breast cancer. Endocrine-Related Cancer 8 175-182.
101. Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D & Hutcheson I 2003 The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80 (Suppl 1) S29-S34; discussion S35.
102. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D & Gee JM 2004 Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 346S-354S.
103. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG & El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Molecular Endocrinology 15 1344-1359.
104. Osborne CK, Coronado E, Allred DC, Wiebe V & DeGregorio M 1991 Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. Journal of the National Cancer Institute 83 1477-1482.
105. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361.
106. Parl FF 2003 Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer. Pharmacogenomics Journal 3 251-253.
107. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia Borrello M, Segatto O, Di Fiore PP & Pelicci PG 1995 Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 11 899-907.
108. Perez-Tenorio G, Stal O & Southeast Sweden Breast Cancer Group 2002 Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. British Journal of Cancer 86 540-545.
109. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX & Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 2435-2446.
110. Pink JJ & Jordan VC 1996 Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Research 56 2321-2330.
111. Pink JJ, Bilimoria MM, Assikis J & Jordan VC 1996 Irreversible loss of the estrogen receptor in T47D breast cancer cells following prolonged estrogen deprivation. British Journal of Cancer 74 1227-1236.
112. Pritchard KI 2003 Endocrine therapy of advanced disease: analysis and implications of the existing data. Clinical Cancer Research 9 460S-467S.
113. Razandi M, Pedram A, Park ST & Levin ER 2002 Proximal events in signaling by plasma membrane estrogen receptors. Journal of Biology Chemistry 278 2701-2712.
114. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L, Gee J & Nicholson RI 2003 Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant estrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proceedings for the American Society of Clinical Oncology 22 7 (Abstract 23).
115. Russell KS & Hung MC 1992 Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Research 52 6624-6629.
116. Saceda M, Knabbe C, Dickson RB, Lippman ME, Bronzert D, Lindsey RK, Gottardis MM & Martin MB 1991 Post-transcriptional destabilization of estrogen receptor mRNA in MCF-7 cells by 12-O-tetradecanoylphorbol-13-acetate. Journal of Biological Chemistry 266 17809-17814.
117. Sachdev D & Yee D 2001 The IGF system and breast cancer. Endocrine-Related Cancer 8 197-209.
118. Salomon DS, Brandt R, Ciardiello F & Normanno N 1995 Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Haematology 19 183-232.
119. Santen RJ 2003 Inhibition of aromatase: insights from recent studies. Steroids 68 559-567.
120. Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W & Shim WS 2001 Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 79 115-125.
121. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Yue W & Berstein L 2003 Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocrine-Related Cancer 10 111-130.
122. Santen RJ, Song RX, Zhang Z, Yue W & Kumar R 2004 Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clinical Cancer Research 10 337S-345S.
123. Schafer JM, Bentrem DJ, Takei H, Gajdos C, Badve S & Jordan VC 2002 A mechanism of drug resistance to tamoxifen in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 83 75-83.
124. Schiff R, Massarweh S, Shou J & Osborne CK 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clinical Cancer Research 9 447S-454S.
125. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK & Osborne CK 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research 10 331S-336S.
126. Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R & Santen RJ 2000 Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141 396-405.
127. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH & Birrer MJ 1999 cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18 6063-6070.
128. Song RX & Santen RJ 2003 Apoptotic action of estrogen. Apoptosis 8 55-60.
129. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J & Santen RJ 2001 Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. Journal of the National Cancer Institute 93 1714-1723.
130. Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S & Yue W 2002a Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Molecular and Cellular Endocrinology 193 29-42.
131. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R & Santen RJ 2002b Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Molecular Endocrinology 16 116-127.
132. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R & Santen RJ 2004 The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. PNAS 101 2076-2081. Epub 2004 Feb 05.
133. Stephen RL, Shaw LE, Larsen C, Corcoran D & Darbre PD 2001 Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. Biological Chemistry 276 40080-40086. Epub 2001 Jul 16.
134. Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD & Martin MB 1997 The role of transforming growth factor-beta in the regulation of estrogen receptor expression in the MCF-7 breast cancer cell line. Endocrinology 138 1498-1505.
135. Stoica A, Saceda M, Doraiswamy VL, Coleman C & Martin MB 2000a Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. Journal of Endocrinology 165 371-378.
136. Stoica A, Saceda M, Fakhro A, Joyner M & Martin MB 2000b Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. Journal of Cellular Biochemistry 76 605-614.
137. Tang CK, Perez C, Grunt T, Waibel C, Cho C & Lupu R 1996 Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Research 56 3350-3358.
138. Tonetti DA, Chisamore MJ, Grdina W, Schurz H & Jordan VC 2000 Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. British Journal of Cancer 83 782-791.
139. Tsuda H 2001 Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer. Breast Cancer 8 38-44.
140. Tzukerman M, Zhang XK & Pfahl M 1991 Inhibition of estrogen receptor activity by the tumor promoter 12-O-tetradeconylphorbol-13-acetate: a molecular analysis. Molecular Endocrinology 5 1983-1992.
141. Vickers PJ, Dickson RB, Shoemaker R & Cowan KH 1988 A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Molecular Endocrinology 2 886-892.
142. Wakeling AE, Nicholson RI & Gee JM 2001 Prospects for combining hormonal and nonhormonal growth factor inhibition. Clinical Cancer Research 7 (Suppl 12) 4350s-4355s; discussion 4411s-4412s.
143. Wells A 1999 EGF receptor. International Journal of Biochemistry and Cellular Biology 31 637-643.
144. Welshons WV & Jordan VC 1987 Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. European Journal of Cancer and Clinical Oncology 23 1935-1939.
145. Wilson MA & Chrysogelos SA 2002 Identification and characterisation of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. Journal of Cellular Biochemistry 85 601-614.
146. Winer EP, Hudis C, Burstein HJ, Byrant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Colbleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ & Browman GP 2003 ASCO technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. Journal of Clinical Oncology 21 2597-2599.
147. Wong ZW & Ellis MJ 2004 First-line endocrine treatment of breast cancer: aromatase inhibitor or antiestrogen? British Journal of Cancer 90 20-25.
148. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG & Davidson NE 2001 Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Research 61 7025-7029.
149. Yarden RI, Wilson MA & Chrysogelos SA 2001 Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. Journal of Cellular Biochemistry 81 232-246.
150. Yu Y & Feig LA 2002 Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells. Oncogene 21 7557-7568.
151. Yue W, Berstein LM, Wang JP, Clark GM, Hamilton CJ, Demers LM & Santen RJ 2001 The potential role of estrogen in aromatase regulation in the breast. Journal of Steroid Biochemistry and Molecular Biology 79 157-164.
152. Yue W, Wang JP, Conaway M, Masamura S, Li Y & Santen RJ 2002 Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143 3221-3229.
153. Yue W, Wang JP, Conaway MR, Li Y & Santen RJ 2003 Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. Journal of Steroid Biochemistry and Molecular Biology 86 265-274.